Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study.
Journal
The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
19
11
2022
revised:
22
04
2023
accepted:
22
04
2023
medline:
31
7
2023
pubmed:
30
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Identification of genetic causes of central precocious puberty have revealed epigenetic mechanisms as regulators of human pubertal timing. MECP2, an X-linked gene, encodes a chromatin-associated protein with a role in gene transcription. MECP2 loss-of-function mutations usually cause Rett syndrome, a severe neurodevelopmental disorder. Early pubertal development has been shown in several patients with Rett syndrome. The aim of this study was to explore whether MECP2 variants are associated with an idiopathic central precocious puberty phenotype. In this translational cohort study, participants were recruited from seven tertiary centres from five countries (Brazil, Spain, France, the USA, and the UK). Patients with idiopathic central precocious puberty were investigated for rare potentially damaging variants in the MECP2 gene, to assess whether MECP2 might contribute to the cause of central precocious puberty. Inclusion criteria were the development of progressive pubertal signs (Tanner stage 2) before the age of 8 years in girls and 9 years in boys and basal or GnRH-stimulated LH pubertal concentrations. Exclusion criteria were the diagnosis of peripheral precocious puberty and the presence of any recognised cause of central precocious puberty (CNS lesions, known monogenic causes, genetic syndromes, or early exposure to sex steroids). All patients included were followed up at the outpatient clinics of participating academic centres. We used high-throughput sequencing in 133 patients and Sanger sequencing of MECP2 in an additional 271 patients. Hypothalamic expression of Mecp2 and colocalisation with GnRH neurons were determined in mice to show expression of Mecp2 in key nuclei related to pubertal timing regulation. Between Jun 15, 2020, and Jun 15, 2022, 404 patients with idiopathic central precocious puberty (383 [95%] girls and 21 [5%] boys; 261 [65%] sporadic cases and 143 [35%] familial cases from 134 unrelated families) were enrolled and assessed. We identified three rare heterozygous likely damaging coding variants in MECP2 in five girls: a de novo missense variant (Arg97Cys) in two monozygotic twin sisters with central precocious puberty and microcephaly; a de novo missense variant (Ser176Arg) in one girl with sporadic central precocious puberty, obesity, and autism; and an insertion (Ala6_Ala8dup) in two unrelated girls with sporadic central precocious puberty. Additionally, we identified one rare heterozygous 3'UTR MECP2 insertion (36_37insT) in two unrelated girls with sporadic central precocious puberty. None of them manifested Rett syndrome. Mecp2 protein colocalised with GnRH expression in hypothalamic nuclei responsible for GnRH regulation in mice. We identified rare MECP2 variants in girls with central precocious puberty, with or without mild neurodevelopmental abnormalities. MECP2 might have a role in the hypothalamic control of human pubertal timing, adding to the evidence of involvement of epigenetic and genetic mechanisms in this crucial biological process. Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, and the Wellcome Trust.
Sections du résumé
BACKGROUND
Identification of genetic causes of central precocious puberty have revealed epigenetic mechanisms as regulators of human pubertal timing. MECP2, an X-linked gene, encodes a chromatin-associated protein with a role in gene transcription. MECP2 loss-of-function mutations usually cause Rett syndrome, a severe neurodevelopmental disorder. Early pubertal development has been shown in several patients with Rett syndrome. The aim of this study was to explore whether MECP2 variants are associated with an idiopathic central precocious puberty phenotype.
METHODS
In this translational cohort study, participants were recruited from seven tertiary centres from five countries (Brazil, Spain, France, the USA, and the UK). Patients with idiopathic central precocious puberty were investigated for rare potentially damaging variants in the MECP2 gene, to assess whether MECP2 might contribute to the cause of central precocious puberty. Inclusion criteria were the development of progressive pubertal signs (Tanner stage 2) before the age of 8 years in girls and 9 years in boys and basal or GnRH-stimulated LH pubertal concentrations. Exclusion criteria were the diagnosis of peripheral precocious puberty and the presence of any recognised cause of central precocious puberty (CNS lesions, known monogenic causes, genetic syndromes, or early exposure to sex steroids). All patients included were followed up at the outpatient clinics of participating academic centres. We used high-throughput sequencing in 133 patients and Sanger sequencing of MECP2 in an additional 271 patients. Hypothalamic expression of Mecp2 and colocalisation with GnRH neurons were determined in mice to show expression of Mecp2 in key nuclei related to pubertal timing regulation.
FINDINGS
Between Jun 15, 2020, and Jun 15, 2022, 404 patients with idiopathic central precocious puberty (383 [95%] girls and 21 [5%] boys; 261 [65%] sporadic cases and 143 [35%] familial cases from 134 unrelated families) were enrolled and assessed. We identified three rare heterozygous likely damaging coding variants in MECP2 in five girls: a de novo missense variant (Arg97Cys) in two monozygotic twin sisters with central precocious puberty and microcephaly; a de novo missense variant (Ser176Arg) in one girl with sporadic central precocious puberty, obesity, and autism; and an insertion (Ala6_Ala8dup) in two unrelated girls with sporadic central precocious puberty. Additionally, we identified one rare heterozygous 3'UTR MECP2 insertion (36_37insT) in two unrelated girls with sporadic central precocious puberty. None of them manifested Rett syndrome. Mecp2 protein colocalised with GnRH expression in hypothalamic nuclei responsible for GnRH regulation in mice.
INTERPRETATION
We identified rare MECP2 variants in girls with central precocious puberty, with or without mild neurodevelopmental abnormalities. MECP2 might have a role in the hypothalamic control of human pubertal timing, adding to the evidence of involvement of epigenetic and genetic mechanisms in this crucial biological process.
FUNDING
Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, and the Wellcome Trust.
Identifiants
pubmed: 37385287
pii: S2213-8587(23)00131-6
doi: 10.1016/S2213-8587(23)00131-6
pmc: PMC7615084
mid: EMS187253
pii:
doi:
Substances chimiques
Follicle Stimulating Hormone
9002-68-0
Gonadotropin-Releasing Hormone
33515-09-2
Luteinizing Hormone
9002-67-9
MECP2 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
545-554Subventions
Organisme : NICHD NIH HHS
ID : R00 HD091381
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00006/2
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R21 HD098684
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R01 HD082314
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Hum Mol Genet. 2007 Mar 15;16(6):640-50
pubmed: 17309881
Ann Neurol. 2010 Dec;68(6):944-50
pubmed: 21154482
Hum Reprod. 2021 Jan 25;36(2):506-518
pubmed: 33313884
Eur J Endocrinol. 2021 Oct 08;185(5):617-627
pubmed: 34403359
Am J Hum Genet. 2001 May;68(5):1093-101
pubmed: 11309679
Pharmazie. 2021 Nov 1;76(11):559-561
pubmed: 34782041
Genet Med. 2020 Jul;22(7):1156-1174
pubmed: 32284538
Pediatr Neurol. 2014 Dec;51(6):769-75
pubmed: 25283752
N Engl J Med. 2013 Jun 27;368(26):2467-75
pubmed: 23738509
Science. 2008 May 30;320(5880):1224-9
pubmed: 18511691
Neural Plast. 2012;2012:415825
pubmed: 22474603
J Clin Endocrinol Metab. 2017 May 1;102(5):1557-1567
pubmed: 28324015
Endocr Rev. 2023 Mar 4;44(2):193-221
pubmed: 35930274
Natl Sci Rev. 2020 Mar;7(3):671-685
pubmed: 34692086
Nat Genet. 1999 Oct;23(2):185-8
pubmed: 10508514
Sci Rep. 2019 Aug 19;9(1):11983
pubmed: 31427717
Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R235-43
pubmed: 15358730
Sci Rep. 2020 Dec 17;10(1):22255
pubmed: 33335218
J Neuroendocrinol. 2009 Feb;21(2):108-22
pubmed: 19187398
Brain Sci. 2021 Jul 09;11(7):
pubmed: 34356138
Sci Rep. 2016 Jun 21;6:28295
pubmed: 27323888
Nat Genet. 2006 Jan;38(1):47-53
pubmed: 16341221
Lancet Diabetes Endocrinol. 2016 Mar;4(3):265-274
pubmed: 26852255
Hum Mol Genet. 2020 Sep 30;29(R1):R89-R99
pubmed: 32681172
Nature. 2010 Nov 11;468(7321):263-9
pubmed: 21068835
Epigenomics. 2015;7(2):247-65
pubmed: 25942534
Nat Commun. 2015 Aug 04;6:7756
pubmed: 26239645
Am J Med Genet B Neuropsychiatr Genet. 2007 Apr 5;144B(3):355-60
pubmed: 17171659
Front Genet. 2021 Jan 21;12:620859
pubmed: 33552148